Edition:
United Kingdom

Foundation Medicine Inc (FMI.OQ)

FMI.OQ on NASDAQ Stock Exchange Global Select Market

136.95USD
20 Jul 2018
Change (% chg)

$0.05 (+0.04%)
Prev Close
$136.90
Open
$136.90
Day's High
$136.95
Day's Low
$136.75
Volume
208,126
Avg. Vol
133,518
52-wk High
$137.10
52-wk Low
$31.70

Chart for

About

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and... (more)

Overall

Beta: -0.09
Market Cap(Mil.): $1,689.42
Shares Outstanding(Mil.): 36.02
Dividend: --
Yield (%): --

Financials

  FMI.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -4.46 -- --
ROI: -96.15 2.22 14.61
ROE: -101.97 3.86 16.34

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

ZURICH/LONDON Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.

19 Jun 2018

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

ZURICH/LONDON Swiss drugmaker Roche is paying $2.4 billion (1.81 billion pounds) to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalise cancer care.

19 Jun 2018

BRIEF-Foundation Medicine Q1 Loss Per Share $1.02

* FOUNDATION MEDICINE ANNOUNCES 2018 FIRST QUARTER RESULTS AND RECENT HIGHLIGHTS

02 May 2018

BRIEF-Dian Diagnostics In Separate Agreements With Foundation Medicine, F. Hoffmann-La Roche

* SAYS IT SIGNS SEPARATE AGREEMENTS WITH FOUNDATION MEDICINE INC, F. HOFFMANN-LA ROCHE LTD ON TUMOUR TREATMENT Source text in Chinese: https://bit.ly/2FlRDHB Further company coverage: (Reporting by Hong Kong newsroom)

27 Apr 2018

BRIEF-Foundation Medicine's New Liquid Biopsy Assay Granted Breakthrough Device Designation By U.S. FDA

* FOUNDATION MEDICINE'S NEW LIQUID BIOPSY ASSAY GRANTED BREAKTHROUGH DEVICE DESIGNATION BY U.S. FOOD AND DRUG ADMINISTRATION

26 Apr 2018

BRIEF-Foundation Medicine - Co, Guardant Health ‍Announced Agreement To Settle False Advertising Challenges

* FOUNDATION MEDICINE - CO, GUARDANT HEALTH ‍ANNOUNCED AGREEMENT TO SETTLE FALSE ADVERTISING CHALLENGES THAT COMPANIES HAD FILED AGAINST EACH OTHER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

13 Mar 2018

BRIEF-Foundation Medicine Reports Qtrly ‍loss Per Share $1.05

* FOUNDATION MEDICINE ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END RESULTS, RECENT HIGHLIGHTS AND 2018 OUTLOOK

07 Mar 2018

BRIEF-Foundation Medicine Enters Into Amended And Restated Ex-US Commercialization Agreement With F. Hoffmann-La Roche Ltd

* FOUNDATION MEDICINE SAYS ON FEB 28, CO ENTERED INTO AMENDED AND RESTATED EX-US COMMERCIALIZATION AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD - SEC FILING

05 Mar 2018

Earnings vs. Estimates